Evidence map›Paper›PMID 23620766›Full record

ArticlePloS one2013

HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer.

Wen-Yee Chay, Sung-Hock Chew, Whee-Sze Ong, Inny Busmanis, Xinyun Li, Sharyl Thung, Lynette Ngo, Sheow-Lei Lim, Yong-Kuei Lim, Yin-Nin Chia and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Options for the Treatment of Mucinous Ovarian Carcinoma.Current treatment options in oncology · 2021
    Review
  11. Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications.EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] · 2020
    Article
  12. Article
  13. Recent Insights into Mucinous Ovarian Carcinoma.International journal of molecular sciences · 2018
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Overexpression of β-catenin and cyclinD1 predicts a poor prognosis in ovarian serous carcinomas.International journal of clinical and experimental pathology · 2014
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Wen-Yee ChayDepartment of Medical Oncology, National Cancer Centre, Singapore, Singapore. chay.w.y@nccs.com.sg
Sung-Hock Chew
Whee-Sze Ong
Inny Busmanis
Xinyun Li
Sharyl Thung
Lynette Ngo
Sheow-Lei Lim
Yong-Kuei Lim
Yin-Nin Chia
Elisa Koh
Cindy Pang
Lay-Tin Soh
Jin Wang
Tew-Hong Ho
Sun-Kuie Tay
Soo-Kim Lim-Tan
Kiat-Hon Lim
John Whay-Kuang Chia
Liang-Kee Goh
Singapore General Hospital · SGKK Women's and Children's Hospital · SGNational Cancer Centre Singapore · SGNanyang Technological University · SGNational University of Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucinous epithelial ovarian cancer has a poor prognosis in the advanced stages and responds poorly to conventional chemotherapy. We aim to elucidate the clinicopathological factors and incidence of HER2 expression of this cancer in a large Asian retrospective cohort from Singapore. Of a total of 133 cases, the median age at diagnosis was 48.3 years (range, 15.8-89.0 years), comparatively younger than western cohorts. Most were Chinese (71%), followed by Malays (16%), others (9.0%), and Indians (5%). 24% were noted to have a significant family history of malignancy of which breast and gastrointestinal cancers the most prominent. Majority of the patients (80%) had stage I disease at diagnosis. Information on HER2 status was available in 113 cases (85%). Of these, 31 cases (27.4%) were HER2+, higher than 18.8% reported in western population. HER2 positivity appeared to be lower among Chinese and higher among Malays patients (p = 0.052). With the current standard of care, there was no discernible impact of HER2 status on overall survival. (HR = 1.79; 95% CI, 0.66-4.85; p = 0.249). On the other hand, positive family history of cancer, presence of lymphovascular invasion, and ovarian surface involvements were significantly associated with inferior overall survival on univariate and continued to be statistically significant after adjustment for stage. While these clinical factors identify high risk patients, it is promising that the finding of a high incidence of HER2 in our Asian population may allow development of a HER2 targeted therapy to improve the management of mucinous ovarian cancers.

Indexed as

Gene AmplificationAdenocarcinoma, MucinousAdolescentAdultAgedAged, 80 and overAsian PeopleCohort StudiesDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesFamilyFemaleHumansMiddle AgedOvarian NeoplasmsSingaporeERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID23620766
PMCPMC3631219
OpenAlexW2045639152

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.